The global liquid biopsy tests market size was valued at USD 673.2 Million in 2025 and is expected to reach USD 2347.79 Million by 2033, at a CAGR of 16.90% during the forecast period

The market growth is largely fueled by increasing adoption of minimally invasive diagnostic techniques, growing prevalence of cancer, and rising demand for personalized medicine and early disease detection

Furthermore, rising awareness among healthcare providers and patients about the advantages of liquid biopsy tests—such as real-time disease monitoring, early detection of tumor recurrence, and reduced need for invasive tissue biopsies—is accelerating the uptake of Liquid Biopsy Tests solutions, thereby significantly boosting the industry's growth